Mazdutide

A Dual Receptor Agonist That Promotes Weight Loss and Blood Glucose Control
Disclaimer: The following product is intended solely for research purposes. We do not promote or encourage any consumption outside of authorised trials.
What Is Mazdutide?
Mazdutide is a new, first-of-its-kind medicine that has been developed for the treatment of obesity and type 2 diabetes. It was approved for use in China in June of 2025, and it can be administered by injection once weekly.
How Does Mazdutide Work?
Mazdutide is a dual receptor agonist, meaning it binds to two different receptors, GLP1R (glucagon-like peptide 1 receptors) and glucagon receptors. This combination that targets receptors is what makes mazdutide unique. GLP-1 is a hormone normally produced by the body in response to eating a meal, and which influences:

Eating behaviour
Metabolism
Insulin secretion
Glucagon is normally secreted in response to low blood glucose levels, fasting, or exercise, to alter metabolism and energy expenditure.

Mazdutide works by:

Activating GLP-1 receptors
Activating glucagon receptors
Activating GLP-1 receptors
Agonises GLP-1 receptors regardless of whether a meal has been ingested or not.
Acting on GLP-1 receptors in the pancreas to stimulate insulin secretion when glucose levels are elevated, and affects GLP-1 receptors in other parts of the body as well, such as the brain and intestines [1].

By activating glucagon receptors, the body responds as though it is in a fasted state, which alters the way energy is metabolised. Activation causes glucose to be released from the liver when blood sugar levels are low, with the increase in blood glucose being counterbalanced by GLP1R agonism. More importantly, the release of glucose is accompanied by an increase in energy expenditure [2].
Mazdutide Benefits
By binding to both GLP-1 receptors and glucagon receptors, Mazdutide brings about the following
benefits:

Reduced appetite and prolonged feeling of satiety
Increased control over blood glucose levels
Increased energy expenditure and weight loss
Reduced appetite and prolonged feeling of satiety

GLP1R activation is responsible for promoting the feeling of satiety, meaning that the desire to eat more food is reduced. Gastric emptying is delayed, so hunger will return later than normal after eating. These combined effects help reduce calorie intake and promote weight loss.
Increased control over blood glucose levels
Delayed gastric emptying results in food leaving the stomach more gradually, so blood glucose levels are less likely to spike. In addition to this, GLP1R activation prevents blood glucose from rising too much after a meal by promoting the secretion of insulin in response to this elevation. The activation of glucagon receptors promotes the release of glucose from the liver in response to low blood sugar levels, reducing the risk of hypoglycaemia. Overall, this dual receptor activation helps to tightly control blood sugar levels.
Increased energy expenditure and weight loss
GLP1R agonists are known to promote energy expenditure by stimulating thermogenesis in brown adipose tissue and the browning of white adipose tissue. Glucagon receptor activation complements this activity by promoting lipid oxidation and thermogenesis. This increased burning of calories leads to weight loss.
Mazdutide Side Effects
The most commonly experienced side effects are gastrointestinal symptoms [3–7], including:
• Nausea
• Vomiting
• Diarrhoea
• Bloating
• Decreased appetite
There have also been cases of hypoglycaemia, although this is not common and does not occur in a significant number of people. These side effects are dose-dependent and can be mitigated by titrating (gradually increasing the dose of) the medication for the first few weeks. Side effects tend to decrease over time as the body adapts to the medicine.
How Mazdutide Compares to Other Similar Drugs
Mazdutide has been found to produce up to a 15% reduction in body weight over 24 weeks, with an average weight loss of 13.3% [3]. In a phase 3 trial, a mean weight reduction of 11% and 14.01% was seen in the groups that took 4mg and 6mg, respectively, after 48 weeks [6].
Semaglutide is another peptide that stimulates GLP-1 receptors. This particular drug does not act on glucagon receptors, only GLP-1R. Studies on semaglutide have found that a mean weight loss of up to 14.9% can be achieved, but over 68 weeks [8]. Mazdutide is therefore able to achieve more rapid weight loss results.
Tirzepatide, like mazdutide, is a dual receptor agonist. It stimulates GLP-1 receptors, just as Mazdutide does, but instead of activating glucagon receptors, it activates GIP receptors. When comparing studies of similar duration on Mazdutide and Tirzepatide, Mazdutide provides greater weight loss results in 24 weeks compared to the 5-7% weight reduction that Tirzepatide offers in 24-26 weeks [9].
Why Buy From Us?

Tamper-proof packaging for product integrity
Customer support from experienced staff
Fast and discreet shipping worldwide
Competitive bulk pricing available for institutions and labs

Conclusion
Mazdutide is a new medicine for treating weight loss and type 2 diabetes. It is capable of promoting significant weight loss results and blood glucose control in a shorter duration of time than other similar medicines. Clinical trials have found it to be well-tolerated with side effects similar to semaglutide, liraglutide, and tirzepatide. It has only recently entered the market, so we will likely see an increase in use over the coming years.
References

Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-
130. doi:10.1016/j.molmet.2019.09.010
Winther JB, Holst JJ. Glucagon agonism in the treatment of metabolic diseases including type
2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26(9):3501-3512.
doi:10.1111/dom.15693
JIANG H, JI L, ZHANG Y, et al. 1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults
with BMI of 30 kg/m2 or more. Diabetes. 2024;73(Supplement_1):1866-LB.
doi:10.2337/db24-1866-LB
Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese
overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.
doi:10.1038/s41467-023-44067-4
Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With
Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes
Care. 2024;47(1):160-168. doi:10.2337/dc23-1287
Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
N Engl J Med. 2025;392(22):2215-2225. doi:10.1056/NEJMoa2411528
Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist
mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A
randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
eClinicalMedicine. 2022;54:101691. doi:10.1016/j.eclinm.2022.101691
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with
Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
Trinh H, Donovan A, McAdam-Marx C. Real-world effectiveness of tirzepatide versus
semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.
Diabetes Obes Metab. 2025;27(6):3523-3525. doi:10.1111/dom.16343